State to share in massive settlement from drug maker
Georgia is one of 43 states that will share in a $105 million settlement with drug maker GlaxoSmithKline over the way the company marketed a trio of drugs.
The London-based firm was accused of improperly marketing asthma drug Advair and the antidepressants Paxil and Wellbutrin. The states alleged that GlaxoSmithKline violated state consumer protection laws by misrepresenting the drugs’ uses.
Georgia will receive roughly $2.6 million. The settlement was announced by the Governor’s Office of Consumer Protection and Attorney General Sam Olens.
“GlaxoSmithKline put Georgia consumers at risk by inappropriately promoting drugs for uses which were not approved by the Food and Drug Administration,” Olens said.
The company was also ordered to continue through March 2019 a program that reduces financial incentives for sales representatives to engage in deceptive marketing. Glaxo also must provide scientifically trained personnel to develop and approve responses to questions from health care providers.
